
    
      Camrelizumab is a humanized antibody for cancer immunotherapy. The National Medical Products
      Administration (NMPA, China) approved camrelizumab as a first-line treatment of certain
      patients with NSCLC. This is a multicenter non-interventional study, NSCLC patients who have
      been treated with camrelizumab will be included. The main objective of this study is to
      evaluate the efficacy and safety of camrelizumab in the clinical practice.
    
  